Tenon Medical (TNON) EBITDA (2021 - 2026)

Tenon Medical has reported EBITDA for 6 years, with the latest figure at -$3.4 million in Q2 2026.

• On a quarterly basis, EBITDA fell 17.4% year-over-year to -$3.4 million in Q2 2026; TTM through Jun 2026 was -$12.9 million, a 0.23% change from a year earlier, with the FY2025 full-year figure at -$12.8 million, up 7.08% from the prior year.
• EBITDA was -$3.4 million for Q2 2026 at Tenon Medical, down from -$3.3 million in the prior quarter.
• The five-year high for EBITDA was -$2.1 million in Q1 2022, with the low at -$7.9 million in Q4 2022.
• Average EBITDA over 5 years is -$3.8 million, with a median of -$3.4 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: EBITDA slumped 1000.0% in 2022, then surged 60.38% in 2023.
• Over 5 years, EBITDA stood at -$7.9 million in 2022, then soared by 60.38% to -$3.1 million in 2023, then decreased by 1.02% to -$3.2 million in 2024, then advanced by 9.68% to -$2.9 million in 2025, then declined by 17.03% to -$3.4 million in 2026.
• The last three EBITDA figures came in at -$3.4 million (Q2 2026), -$3.3 million (Q1 2026), and -$2.9 million (Q4 2025), per Business Quant data.